Since January 2018, T3 BioScience is funding R&D into the rare disease cystic fibrosis. A proprietary strategy has been developed in identifying compounds that could be developed as a cure into this rare genetic disease. T3's established medical screening process will be applied to this initiative. This rare disease is a genetic disorder, affecting mostly the lungs but also the pancreas, liver, kidney and intestines. Long-term issues include difficulty of breathing a coughing up mucus as a result of lung infections. The antibiotic resistant "superbug" Pseudomonas aeruginosa pathogen appears on cystic fibrosis, resulting in T3 deciding to fund this important initiative.